Try it free

H

Henlius Biopharmaceuticals

Sustainability Report and Carbon Intensity Rankings

45301 Employees
Website
Linkedin

Is Henlius Biopharmaceuticals doing their part?

Their DitchCarbon score is 51

Henlius Biopharmaceuticals has a DitchCarbon Score of 51, indicating a moderate level of sustainability in their operations. This score reflects the company’s carbon intensity, which is a measure of how much carbon emissions are produced relative to their activity. A score of 51 suggests that Henlius Biopharmaceuticals is making progress but still has room for improvement in reducing its carbon footprint.

This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.

Industry emissions intensity

Very low

Low

Medium

High

Very high

Henlius Biopharmaceuticals is part of the research and development sector, which has a carbon intensity ranking of very low. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.

Location emissions intensity

Very low

Low

Unknown

High

Very high

Henlius Biopharmaceuticals, located in China, operates in a region with a specific carbon intensity rating. The sustainability of the company’s operations is influenced by China’s overall carbon intensity, affecting its environmental impact.
0.36%

...this company is doing 0.36% worse in emissions than the industry average.

Henlius Biopharmaceuticals, Inc., founded in the research and development sector, is a biotechnology firm based in Fremont, California, United States. Established at 48860 Milmont Drive, the company specializes in the discovery and development of innovative biopharmaceuticals. Henlius offers a range of services including drug development, clinical trials, and the commercialization of therapeutic antibodies.
Compare Henlius Biopharmaceuticals with other companies in the same industry –>

emission intelligence's platform recommendations for Henlius Biopharmaceuticals

Henlius Biopharmaceuticals should undertake a thorough inventory of all Scope 1 emissions sources to identify and mitigate direct greenhouse gas emissions.
Full recommendation sample, Adobe ->

Bad news, Henlius Biopharmaceuticals hasn't committed to SBTi yet

Henlius Biopharmaceuticals has not yet established specific commitments with the Science Based Targets initiative (SBTi). This means the company is either in the process of setting or has not publicly disclosed its goals for reducing greenhouse gas emissions in line with climate science.
Not participating

The Ultimate Guide to Building Sustainability Into Procurement​

1. Reputation and Brand Image

2. Corporate Social Responsibility

3. Becoming a Customer of Choice

4. Stakeholder Engagement

5. Risk Management

Download PDF

Case study — How Compleat's clients use our carbon data

Making Compleat’s customers climate heroes. Download the 19-page case study PDF.
Download

Claim this profile

Are you associate with this company?
Help us improve our data and claim this profile.

Claim this profile ->

Our methodology

Read about our emission calculation methodologies, and what the DitchCarbon Score means.

Learn about our methodology ->

Other company reports in this industry

Looking for a specific company?

Search our company directory or contact us for custom data requests.
Full list of companies
Contact us

Quicklinks

About
Privacy Policy
License agreement
Billing
Login

Resources

Blog
API documentation
Industry sustainability reports
Find a company's emissions data
Free to use SBTi API

Get in touch

Email: enquiries@ditchcarbon.com
Tel: +44 203 475 7875
Office: Ditch Carbon Ltd
167-169 Great Portland Street
London W1W 5PF
Linkedin
DitchCarbon Limited © 2024